March 10, 2023
Mika Turkia
1 citation
preprint
In February 2023, Australia became the first country in the world to allow psychiatrists to prescribe 3,4-methylenedioxymethamphetamine (MDMA) for post-traumatic stress disorder (PTSD). This may have left interested clinicians looking for practical examples of the use of MDMA. In the 1950s and 1960s, psychedelics were successfully utilized in the treatment of alcoholism. This case study, the...
March 10, 2023
Mika Turkia
preprint
In recent psychedelic therapy research, the concept of 'mystical experience' has been highlighted, as in several studies it has been identified as a significant predictor of improved outcome. Many studies mentioning the concept, for example, reports of randomized clinical trials, typically do not provide detailed examples of such experiences, however. In order to make the concept easily...
March 10, 2023
Michiel van Elk, Eiko I. Fried
30 citations
preprint
Research in the last decade has expressed considerable optimism about the clinical potential of psychedelics for the treatment of mental disorders. This optimism is reflected in a considerable increase in research papers, investments by pharmaceutical companies, patents, media coverage, as well as political and legislative changes. However, psychedelic science is facing serious challenges that...
March 10, 2023
Mika Turkia
4 citations
preprint
In medicine, psychedelics were initially considered as a tool for clinicians to understand psychotic states. Based on the presented case data, a reversal of that concept is proposed: psychedelics could be conceptualized as a tool for people chronically anxious and depressed since early childhood to understand ordinary states of mind (e.g. calmness, hopefulness, relaxation, and joy). The case...
ACS Pharmacology & Translational Science
March 10, 2023
Marilyn Naeem, Grant C. Glatfelter, Duyen N. K. Pham et al.
25 citations
Analogues of 4-phosphoryloxy-N,N-dimethyltryptamine (psilocybin) are being sold on recreational drug markets and developed as potential medications for psychedelic-assisted therapies. Many of these tryptamine-based psilocybin analogues produce psychedelic-like effects in rodents and humans primarily by agonist activity at serotonin 2A receptors (5-HT2A). However, the comprehensive...
Psychedelics as Psychiatric Medications
March 1, 2023
Laurie Higbed, Ben Sessa
Abstract Psychedelic compounds offer a unique type of mental health treatment. This chapter considers how psychedelics can be explored as an alternative to the typical maintenance medication for the treatment of symptoms, through using psychedelic medicines in a controlled clinical setting as an adjunct to psychotherapy. In combination with psychotherapy, the psychedelic experience provides the...
Psychedelics as Psychiatric Medications
March 1, 2023
Joanna C. Neill, Mohammed Shahid, Rosalind Gittins et al.
Abstract Improved understanding of the potential risks and adverse effects of psychedelics is essential before psychedelic-assisted therapy is adopted into mainstream medicine. In spite of numerous recent clinical trials, gaps in knowledge remain. A comprehensive analysis of human receptor pharmacology is required to inform clinical dosing strategies and improve the understanding of drug-drug...
European Psychiatry
March 1, 2023
V. W. L. Tsang, R. Moyer, P. Kryskow et al.
2 citations
IntroductionHealthcare practitioners (HCPs) are facing a mental health crisis. Group therapies have long been used to treat symptoms associated with PTSD, anxiety and/or depression, however no studies have investigated the role of implementing group therapy with and without ketamine-assisted therapies (KaT).ObjectivesThe current study investigated the effects of the Roots to Thrive (RTT) group...
Psychedelics as Psychiatric Medications
March 1, 2023
Michael C Mithoefer, David E. Presti
Abstract MDMA (3,4-methylenedioxymethamphetamine) was originally synthesized and patented by the Merck chemical company in 1914. It was not explored for human use until the 1970–80s when there were published reports that it could be a useful catalyst to psychotherapy, in part because it often produced reduced anxiety and increased emotional openness. In 1985, in response to media attention to...
European Psychiatry
March 1, 2023
V. W. L. Tsang, Brendan Tao, Shannon Dames et al.
1 citation
IntroductionKetamine has been increasingly used to treat mental health conditions yet there is a lack of safety data on intramuscular (IM) and sublingual (SL) dosing in a community setting. The Roots to Thrive Ketamine assisted Therapy (RTT-KaT) program is a 12-week program with 12 Community of Practice (CoP) group therapy sessions and three ketamine sessions.ObjectivesTo provide preliminary...